Scrip
US FDA advisors unimpressed by Arena's Lorqess
17 September 2010
Daniel B. Moskowitz
The US FDA's endocrinologic and metabolic drug advisory committee has recommended against approving Arena Pharmaceuticals'weight-loss drug Lorqess (locaserin), its lead drug candidate. On the question of whether the available data demonstrate that the potential benefits of locaserin outweigh
17 September 2010
Daniel B. Moskowitz
The US FDA's endocrinologic and metabolic drug advisory committee has recommended against approving Arena Pharmaceuticals'weight-loss drug Lorqess (locaserin), its lead drug candidate. On the question of whether the available data demonstrate that the potential benefits of locaserin outweigh
No hay comentarios:
Publicar un comentario